- Delpharm will invest $220 million to modernise its Boucherville facility, supported by federal and provincial funding.
- The project will expand production capacity, add a new sterile filling line, and renew 95% of equipment by 2031.
Delpharm has announced a $220 million investment to modernise its pharmaceutical facility in Boucherville, Quebec. The funding includes $60 million from the provincial government, $60 million from the federal government, and $100 million in private capital. The company said the project will transform the site into a world-class facility by 2031.
The modernisation will expand the plant, introduce a new sterile filling line, and renew 95% of current equipment. According to the company, this will significantly increase production capacity to meet growing demand for injectable medicines.
Christine Fréchette, Quebec’s Minister of Economy, Innovation and Energy, said: “By partnering with Delpharm and investing in its success, our government is ensuring the strengthening of our supply chains and the sustainability of demand in the hospital market.”
Delpharm plays a key role as a supplier to Quebec’s health network, which relies heavily on the medicines produced at its Boucherville facility. The site is the largest in Canada dedicated to sterile injectable production, with a substantial share supplied to both Quebec and Canadian markets. The new investment will enhance Delpharm’s ability to innovate and expand production. “Congratulations to the company on this forward-looking expansion,” said Christian Dubé, Minister of Health.
“We thank the Ministry of Economy, Innovation and Energy for supporting Quebec’s pharmaceutical autonomy and acknowledge our long-standing partner Sandoz, with whom we have renewed a 10-year contract to produce hospital generics. This ensures patients in Quebec and Canada benefit from a stable and reliable local supply.” Mathieu Grondin, Director, Delpharm Boucherville
